Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Receivables: 2011-2024

Historic Receivables for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $59.0 million.

  • Mimedx Group's Receivables rose 47.20% to $83.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.9 million, marking a year-over-year increase of 22.48%. This contributed to the annual value of $59.0 million for FY2024, which is 3.41% up from last year.
  • Mimedx Group's Receivables amounted to $59.0 million in FY2024, which was up 3.41% from $57.0 million recorded in FY2023.
  • Mimedx Group's 5-year Receivables high stood at $59.0 million for FY2024, and its period low was $36.4 million during FY2020.
  • Its 3-year average for Receivables is $54.3 million, with a median of $57.0 million in 2023.
  • Data for Mimedx Group's Receivables shows a peak YoY rose of 21.65% (in 2023) over the last 5 years.
  • Mimedx Group's Receivables (Yearly) stood at $36.4 million in 2020, then rose by 14.25% to $41.5 million in 2021, then grew by 12.82% to $46.9 million in 2022, then climbed by 21.65% to $57.0 million in 2023, then rose by 3.41% to $59.0 million in 2024.